文献速递肿瘤 PET/CT

68Ga-PSMA I&T PET/CT用于前列腺癌初始分期

68Ga-PSMA I&T PET/CT for primary staging of prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-09-16

结果显示PSMA阳性病灶见于83%患者,淋巴结及远处转移主要见于中高危组,低危组无前列腺外病变,淋巴结转移检测特异度98.4%、准确率93.0%。

要点

  • 68Ga-PSMA I&T PET/CT在中高危前列腺癌初始分期中可识别淋巴结和远处转移。
  • 低危前列腺癌中前列腺外病变患病率低,该检查价值似乎有限。
  • 与病理对照,淋巴结转移检测灵敏度35.0%、特异度98.4%、准确率93.0%。

核心结论

  • 在中高危初诊前列腺癌患者中,68Ga-PSMA I&T PET/CT通过识别淋巴结和/或远处转移而成为相关分期手段。
  • 由于前列腺外病变患病率低,其在低危疾病中的价值似乎有限。

研究设计与样本

  • 回顾性分析新诊断、未治疗、拟行根治性治疗前的前列腺癌患者,共82例。
  • 82例中低危11例、中危32例、高危39例。

主要发现

  • 83%患者检出PSMA阳性病变,66/82(80.5%)原发肿瘤可见。
  • PSMA avid淋巴结见于17/82(20.7%),其中中危3例、高危14例。
  • 远处病变见于14/82(17.1%),其中中危2例、高危12例。
  • 低危前列腺癌中未发现前列腺外病变。
  • 原发肿瘤SUVmax与血清PSA值(r=0.51,p<0.001)及Gleason评分(r=0.35,p=0.001)分别呈弱但显著相关。

关键数值与推荐

  • 与病理对照,淋巴结转移检测的每区域灵敏度35.0%、特异度98.4%、阳性预测值63.6%、阴性预测值95.0%、准确率93.0%。

临床怎么用

  • 对初诊中高危前列腺癌患者,可考虑行68Ga-PSMA I&T PET/CT以评估淋巴结和远处转移。
  • 对低危前列腺癌患者,因前列腺外病变患病率低,该检查的分期价值似乎有限。

局限性

  • 本研究为回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The present study is based on a retrospective analysis of Gallium-68 (68Ga)-labelled prostate-specific membrane antigen (68Ga-PSMA I&T) PET/CT performed in newly diagnosed, treatment-naïve prostate cancer (PCa) patients prior to definitive treatment. METHODS: A total of 82 men were included in the study and were imaged with 68Ga-PSMA I&T PET/CT to assess the distribution of PSMA-avid disease for staging purposes (11 with low-risk, 32 with intermediate-risk, and 39 with high-risk PCa). Forty patients (20 with intermediate- and 20 with high-risk disease) underwent subsequent radical prostatectomy with extended pelvic lymph node dissection which allowed for correlation of imaging findings with histopathologic data. RESULTS: PSMA-positive disease was detected in 83% of patients with 66/82 (80.5%) primary tumours being visualized. PSMA-avid lymph nodes were recorded in 17/82 patients (20.7%, 3 with intermediate-risk and 14 with high-risk PCa); distant disease was found in 14/82 subjects (17.1%, 2 with intermediate-risk and 12 with high-risk PCa). No extraprostatic disease was found in low-risk PCa. SUVmax of primary tumours showed a weak but significant correlation with serum PSA values (r = 0.51, p < 0.001) and Gleason scores (GSC; r = 0.35, p = 0.001), respectively. In correlation with histopathology, calculated per-region sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for detection of lymph node metastases were 35.0%, 98.4%, 63.6%, 95.0%, and 93.0%, respectively. CONCLUSIONS: In patients with initial diagnosis of intermediate- and high-risk prostate cancer, 68Ga-PSMA I&T PET/CT emerges as a relevant staging procedure by identifying nodal and/or distant metastases. Due to the low prevalence of extraprostatic disease, its value seems to be limited in low-risk disease.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cytawa W, Seitz AK, Kircher S, et al. 68Ga-PSMA I&T PET/CT for primary staging of prostate cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31529265. doi:10.1007/s00259-019-04524-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。